CD274 and neoplasm: Given that PD-L1 expression serves as a predictive biomarker for the response to immunotherapy (7) and preexisting data indicate PD-L1 inducing effects of neoadjuvant CRT in other tumor entities (8), it is plausible that neoadjuvant chemoradiotherapy could increase surface PD-L1 expression and thereby improve clinical outcomes.